MCRI to build on CyGenics' stem cell scaffold
Friday, 13 August, 2004
Stem cell company CyGenics (ASX: CYN) will collaborate with the Murdoch Children's Research Institute to perform clinical trials demonstrating that stem cells expanded from umbilical cord blood using CyGenics subsidiary Cytomatrix's proprietary cell growth scaffold retain full functionality and effectiveness.
Cytomatrix will transfer the technology, which has been shown to work for the expansion of human bone marrow stem cells, cord blood stem cells and peripheral blood stem cells, to researchers working at the MCRI.
A grant of AUD$50,000 has been awarded to the company through the Federal Government's International Science Linkages Program to support the trials.
The microbiome helps to fight melanoma
Molecules produced by gut bacteria upon digestion of dietary fibre can improve the function of...
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
